Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 1st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 1st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 30th 2013

For Cancer Survivors, 2014 Will Be the Year to Plan

The coming year will be one for those who have beaten cancer to develop survivorship plans, with the Commission on Cancer to require planning by treatment centers starting in 2015.

December 28th 2013

Discussion 8: Redefining the Role of Industry in Contemporary Healthcare

Cliff Goodman, PhD John L. Fox, MD, MHA Bo Gamble

The final panel of the conference analyzes the role of the industry in healthcare, including panelists' observations on topics such as innovation. Mr Gamble, for instance, offers his insights as to how groups like the Community Oncology Alliance are working with the industry to drive the message about the quality and the value component throughout all the stakeholders. Dr Fox provides perspective on how payers can offer valuable partnerships throughout the industry, including those with pharmaceutical companies.

December 28th 2013

Discussion 7: Value-Based Pricing: The Role of Outcomes Data in Pricing Models

Cliff Goodman, PhD Jeffrey D. Dunn, PharmD, MBA Michael E. Chernew, PhD Kirby Eng, RPh

Dr Cliff Goodman leads a discussion featuring panelists including The American Journal of Managed Care's co-editor-in-chief, Dr Michael Chernew. Topics of the discussion include the impact of value-based pricing in the market, and how different pricing models such as bundled payments or accountable care organizations impact risk factors.

December 28th 2013

Presentation 7: Where Does HEOR Fit in the Oncology Model?

Scott D. Ramsey, MD, PhD

According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.

December 28th 2013

Discussion 6: Nextâ€Generation Genetic Sequencing in Oncology: Ready for Prime Time?

Ira M. Klein, MD, MBA, FACP Michael Kolodjiez, MD Lee N. Newcomer, MD, MHA John L. Fox, MD, MHA Jerry Conway

Mr Klein leads another discussion with Michael Kolodjiez, MD, Lee N. Newcomer, MD, MHA, John L. Fox, MD, MHA, and Jerry Conway. The panel responds to whether there are gaps in targeted gene analyses. They also discuss other issues including bioinformatics, and how payers, providers, and pharmacists might collaborate on improving care through genetic sequencing.

December 28th 2013

Presentation 6: The Present (and Future) of Genetic Profiling in Oncology

Jerry Conway

Jerry Conway provides a DNA-centric view of organizing treatment plans with respect to the use of some advances in genomic technology.

December 28th 2013

Discussion 5: Companion Diagnostics in Targeted Treatments

Ira M. Klein, MD, MBA, FACP Jan Berger, MD, MJ Mike Kolodziej, MD

Dr Klein moderates this discussion, including co-editor in chief of The American Journal of Pharmacy Benefits Dr Jan Berger. The panel addresses a variety of topics as they relate to companion diagnostics in targeted treatments. Panelists respond to issues such as who should take responsibility in genetic counseling to ensure that patients have the best experience possible-whether it be in person or telephonic. Other topics covered in this discussion include appropriate consumerism in this space, the employer's role in genetic counseling, and how medical professionals are being trained or educated about these processes.

December 28th 2013

Presentation 5: Payer Perspectives on Genetic Counseling

Karen Lewis, MS, MM, CGC

Karen uses this session to analyze payer perspectives in genetic counseling. She describes the process involved with genetic counseling and the role of the counselor. She notes that the path to becoming a genetic counselor can often be more rigorous than in other specialties. Ms Lewis also discusses the surge of interest that genetic counseling has seen in recent years.

December 28th 2013

Presentation 4: An Update on Clinical Pathways

Bruce A. Feinberg, DO

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.

December 28th 2013

Discussion 3: Challenges and Opportunities for Quality Measures in Oncology

Ira M. Klein, MD, MBA, FACP Lee N. Newcomer, MD, MHA Phyllis Torda Dennis Scanlon, PhD

Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are not enough PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the nimbleness of structuring data.

December 28th 2013

Presentation 3: Defining and Measuring Quality Outcomes in Oncology

Lee N. Newcomer, MD, MHA

Dr Newcomer says that he welcomes the transition of oncology from being evaluated in process measures to outcome measures. He says that while quality measures can be quick and messy, these results are used for the purpose of finding gaps and seeing if those gaps can be improved.

December 28th 2013

Discussion 2: Implications of Healthcare Reform: 'Noâ€ Will Be Heard

Cliff Goodman, PhD A. Mark Fendrick, MD John L. Fox, MD, MHA Ira M. Klein, MD, MBA, FACP

Implications of Healthcare Reform: 'No' Will Be Heard is led by Cliff Goodman, PhD, in a panel discussion featuring A. Mark Fendrick, MD, co-editor in chief of The American Journal of Managed Care, John L. Fox, MD, MHA, and Ira M. Klein, MD, MBA, FACP. The panelists determine what it means when a patient says no.

December 28th 2013

Presentation 2: Incorporating Patient-Centered Outcomes in Clinical Trials

Ethan Basch, MD

Ethan Basch, MD, a self-described triple-threat, discusses incorporating patient-centered outcomes into clinical trials. He begins his presentation by describing a colleague's published research article, Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. The study found that not only did Pazopanib cost an estimated $5800 and Sunitinib $7800, but Pazopanib was superior to Sunitiniib in 11 out of 14 quality-of-life indicators.

December 28th 2013

Presentation 1: Oncology Practice in the Era of PCMHs and ACOs: Square Pegs or Round Holes?

Peter B. Bach, MD, MAPP

Dr Peter Bach says professionals are looking at opportunities for new payment models and care redesign, but there are also threats that might surface. Each type of insurance payment model has different levels of risk factors. New payment models, such as the UHC pathways program and CMMI demo, have limited risk.

December 26th 2013

Value of Genetic Testing in Breast Cancer

Katie Sullivan

The value of genetic testing in breast cancer is subject to debate, but it also holds promise. One recent clinical trial simulated by a group of researchers, for instance, found that the 7 single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was cost-effective when used for MRI screenings in patients at intermediate risk of developing the disease over their lifetime.

December 23rd 2013

Economics of Genomic Testing for Women With Breast Cancer

Robert D. Lieberthal, PhD

All the economic studies of genomic tests for breast cancer rely on modeling rather than randomized controlled trials or other direct trial data.

December 20th 2013

Outrage at the Increasingly High Cost of Cancer Drugs

Cancer drug prices have doubled in the past decade, from an average of $5,000 per month to more than $10,000.

December 13th 2013

The Quest for Better Survivorship: Guidelines Promote More Accountable Cancer Care

Peter Page

December 13th 2013

FDA Approves Ibrutinib for Mantle Cell Lymphoma

Silas Inman

December 13th 2013

Genetic Testing Should Come With Counseling: American Cancer Society CMO, Supreme Court Plaintiff Among Experts Who Warn of Consumer Risks

Nicole Beagin

December 13th 2013

Oncology Groups Active in Effort to Repeal SGR

Mary K. Caffrey

December 13th 2013

Current Thinking Behind Decision Making in Oncology Clinical Pathway Design

Rhonda Greenapple, MSPH

December 8th 2013

Treating the Signs of Multiple Myeloma Before it Starts

Progress in treating multiple myeloma, or cancer of the plasma cells in bone marrow, has advanced significantly over the past decade. Today, questions about the disease often involve finding a treatment that balances the goal of putting a patient into remission especially if stem cell transplantation is a possibility against the toxicity of the treatment itself.

December 8th 2013

Collaboration Between Academia and Pharma to Bring New Therapies to Market More Important Than Ever

With grants from government sources looking less certain, partnerships between academic research center and pharmaceutical companies are more important than ever to keep breakthrough hematology therapies in the pipeline, said Burt Adelman, MD, a hematologist who serves as executive vice president and chief medical officer for Dyax Inc.

December 8th 2013

In Treating Older CLL Patients, Cost Considerations Are a Factor

New therapies to treat chronic lymphocytic leukemia (CLL) will receive plenty of attention this week at the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. At an education session that opened the meeting Saturday, a physician with the Mayo Clinic made it clear that cost considerations are a reality for many older patients.

November 27th 2013

Doctors Argue for Decision Aids to Promote Patient Engagement

Research on how tools impact health, costs is 'inconclusive,' but clinicians say better-informed patients avoid unnecessary care, frustration

November 26th 2013

Episode 13 - Final Insights

November 26th 2013

Episode 12 - Specialty Pharmacy's Role in CRPC

November 26th 2013

Episode 11 - Personalized Medicine in CRPC

November 26th 2013

Episode 10 - End-of-Life Care in CRPC

...

168 169 170 171 172 173 174 175 176

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions